A Longitudinal Cohort Study of Denosmab and Bisphosphonate for Prevention of Vertebral Fracture in Glucocorticoid-Induced Osteoporosis in Japanese

Ikuko Tanaka¹, Mari Ushikubo², Keisuke Izumi², Kumiko Akiya³ and Hisaji Oshima³, ¹NAGOYA Rheumatology Clinic, Nagoya, Japan, ²Department of Rheumatology, National Tokyo Medical Center, Tokyo, Japan, ³Department of Connective Tissue Diseases, National Tokyo Medical Center, Tokyo, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Osteoporosis and rheumatoid arthritis (RA)

Session Information

Date: Sunday, November 13, 2016

Title: Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: In recent years, denosumab, a monoclonal antibody against RANKL, has been proven for effective treatment of primary osteoporosis. However, effects of denosmab for glucocorticoid-induced osteoporosis(GIOP) were not clearly resolved. We conducted a longitudinalcohort study to clarify effects of denosmab when compared with bisphosphonates on osteoporotic vertebral fractures in GIOP.

Methods: Patients with connective tissue diseases at Tokyo Medical Center was subjected for one year longitudinal cohort study. The number of subjects was 210 (female; 184, age; 65+/-14 (mean +/- SD), prednisolone dosage during 1yr; 6.2+/-5.1mg/day, disease duration; 11.7+/-11.3yr). Lumbar bone mineral densities (lBMD) were measured with Lunar 3030 (GE). Incident vertebral fractures were defined from XP with the semi-quantitated method (Genant, H. 1993). Prevalent vertebral fractures were seen in 97（46％） patiets. Bisphosphonates and denosmabwere used in 150 and 60 patients, respectively.

Results: 1) The value of lBMD (%YAM) at the base line was 81.7+/-14.7%. The rate of incident fractures during the follow-up period was 12.3%. 2) The group of denosmab showed higher values in age and prevalent fracture and lower value in lBMD than the group of Bisphosphonates (p<0.05). Increases in lBMD after 1 yr were not different in these two groups. Incident vertebral fractures were lower in the patients with denosmab (3.3%) than in those with bisphosphonates (16.0%), even though the denosmab group were at higher risk in age, prevalent fracture, and lBMD. 3) A logistic regression analysis revealed that statistically significant factors for incident fractures were lBMD (1% increase, OR; 0.95; 95%CI; 0.91-0.99, p<0.01), prednisolone dosages (1mg/day increase, 1.13, 1.03-1.25, p<0.01), prevalent fractures (3.61, 1.29-10.13, p<0.01), and denosmab treatment (vs bisphosphonates, 0.17, 0.03-0.54, p<0.01).

Conclusion: Our results suggested that denosmab might be effective for prevention of osteoporotic fractures in patients treated with glucocorticoids.

Disclosure: I. Tanaka, None; M. Ushikubo, None; K. Izumi, None; K. Akiya, None; H. Oshima, None.

To cite this abstract in AMA style:

Tanaka I, Ushikubo M, Izumi K, Akiya K, Oshima H. A Longitudinal Cohort Study of Denosmab and Bisphosphonate for Prevention of Vertebral Fracture in Glucocorticoid-Induced Osteoporosis in Japanese [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/a-longitudinal-cohort-study-of-denosmab-and-bisphosphonate-for-prevention-of-vertebral-fracture-in-glucocorticoid-induced-osteoporosis-in-japanese/. Accessed .

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-longitudinal-cohort-study-of-denosmab-and-bisphosphonate-for-prevention-of-vertebral-fracture-in-glucocorticoid-induced-osteoporosis-in-japanese/